Biotechnology
Intercept Pharmaceuticals Plunged Today, Here’s Why
On Thursday, September 21, as of 3:26 p.m. EDT, Intercept Pharmaceuticals (NASDAQ:$ICPT) plunged 21%. What happened? Well, the fall began after the FDA released a safety announcement warning the public that when Intercept’s liver disease ... [Read]
![Iovance Biotherapeutics, Inc.](https://microsmallcap.com/wp-content/uploads/2017/10/Iovance-Biotherapeutics-Inc-Sets-Prices-for-50-Million-Common-Stock-Offering-374x295.jpg)
Biotechnology
Iovance Biotherapeutics, Inc. Sets Prices for $50 Million Common Stock Offering
Iovance Biotherapeutics, Inc (NASDAQ:$IOVA) has announced pricing for their $50 million common stock offering. The company will offer 7,692,308 shares of its common stock at the price of $6.50 per share. Gross profits from this ... [Read]
![VBI Vaccines, Inc.](https://microsmallcap.com/wp-content/uploads/2017/10/Zacks-Investment-Research-Upgrades-VBI-Vaccines-Rating-374x295.jpg)
Biotechnology
Zacks Investment Research Upgrades VBI Vaccines, Inc.’s Rating
In a report published on Tuesday morning, Zacks Investment Research has upgraded its rating of VBI Vaccines, Inc (NASDAQ:$VBIV) from a ‘Sell’ rating to a ‘Hold’. VBIV is a biotechnology company that is focused on ... [Read]
![VBI Vaccines](https://microsmallcap.com/wp-content/uploads/2017/10/VBI-Vaccines-Rating-Upgraded-by-Zacks-Investment-Research-374x295.jpg)
Biotechnology
VBI Vaccines’ Rating Upgraded by Zacks Investment Research
VBI Vaccines Inc (NASDAQ:$VBIV) saw its stock rating with Zacks Investment Research rise from ‘Sell’ to ‘Hold’ in a research note from Tuesday. VBIV is a biopharmaceuticals company that develops new technology focused on expanding ... [Read]
![Best Time to Buy Iovance Biotherapeutics](https://microsmallcap.com/wp-content/uploads/2017/10/This-is-Why-Right-Now-is-the-Best-Time-to-Buy-Iovance-Biotherapeutics-374x295.jpg)
Biotechnology
This is Why Right Now is the Best Time to Buy Iovance Biotherapeutics
Iovance Biotherapeutics Inc. (NASDAQ:$IOVA) is a huge mover this week as shares have increased 5.10%, or $0.4 during the last trading session. In total, about 568,977 shares have been traded, 39.85% up from the average. ... [Read]
Biotechnology
Nabriva Therapeutics Stock Increased Today, Here’s Why
If you’re looking to get into biotech investing, you might want to think about adding Nabriva Therapeutics (NASDAQ:$NBRV) to your investment portfolio. For the second day in a row, the company is witnessing double-digit gains. ... [Read]
![Spectrum Pharmaceuticals, Inc.](https://microsmallcap.com/wp-content/uploads/2017/10/The-Road-Ahead-for-Spectrum-Pharmaceuticals-374x295.jpg)
Biotechnology
The Road Ahead for Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc. (NASDAQ:$SPPI) experienced a disappointing day during trading on Monday, September 18. The stock dipped -0.69% to a closing price of $10.10. The stock normally trades 894.52 million shares a day, but on ... [Read]
Biotechnology
The Recipe Behind Abeona Therapeutics’ 6 Months Dominance
As of 2:50 EDT, Abeona Therapeutics (NASDAQ:$ABEO) have surged a whopping 18%. This came after an analyst from RBC Capital granted the biotech company an outperform rating and assigned a $23 price target, more than ... [Read]
![VBI Vaccines](https://microsmallcap.com/wp-content/uploads/2017/10/Here-is-What-You-Need-to-Measure-VBI-Vaccines-Incs-Momentum--374x295.jpg)
Biotechnology
Here is What You Need to Measure VBI Vaccines Inc.’s Momentum
As of morning trading, VBI Vaccines Inc. (NASDAQ:$VBIV) shares are revealing a strong upward momentum, with the Aroon indicator reading above 70. Many investors are intrigued. Let’s look at the different metrics of measurement used ... [Read]
![Rating for Spectrum Pharmaceuticals](https://microsmallcap.com/wp-content/uploads/2017/10/Trilogy-Metals-Inc-Enters-Active-Mover-List.-374x295.jpg)
Biotechnology
Analysts’ September Coverage Rating for Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc. (NASDAQ:$SPPI) is a biotechnology company with a market cap of $857.70 million. The company specialized in the development and commercialization of oncology and hematology drugs. Despite operating through negative earnings currently, Spectrum ... [Read]